MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ
61.60
+0.77
+1.27%
After Hours: 62.54 +0.94 +1.53% 16:31 04/22 EDT
OPEN
61.47
PREV CLOSE
60.83
HIGH
63.22
LOW
60.91
VOLUME
627.17K
TURNOVER
0
52 WEEK HIGH
82.04
52 WEEK LOW
41.57
MARKET CAP
6.70B
P/E (TTM)
-14.8781
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PCVX last week (0415-0419)?
Weekly Report · 17h ago
Weekly Report: what happened at PCVX last week (0408-0412)?
Weekly Report · 04/15 09:20
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Vaxcyte Inc estimates pneumococcal conjugate vaccines market will grow to $12 billion in the next few years. The market is currently split into 25% adults and 75% infants. Needham maintains the Buy rating with a price target of $95 for the company.
Benzinga · 04/10 18:42
Vaxcyte Price Target Maintained With a $95.00/Share by Needham
Dow Jones · 04/10 11:29
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/10 10:50
Weekly Report: what happened at PCVX last week (0401-0405)?
Weekly Report · 04/08 09:21
Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst
Needham analyst says Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma. The three companies are the most likely to be acquired in Needham's coverage universe. Needham expects M&A activity to remain above average for the remainder of 2024.
Seeking Alpha · 04/07 12:00
Weekly Report: what happened at PCVX last week (0325-0329)?
Weekly Report · 04/01 09:21
More
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Webull offers Vaxcyte Inc stock information, including NASDAQ: PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.